Pharming Group provides update on previously announced G&A expense reduction plan
Corporate updatesPharming Group today announced the implementation of an organizational restructuring to accelerate the Company’s growth.
2025
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Operational updates
Pharming Group promoted to the Euronext AMX® index
Corporate updatesPharming Group N.V. today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Conference attendancePharming Group N.V. announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
Corporate updatesPharming Group N.V. today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025.
Pharming Group to participate in August investor conference
Conference attendancePharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of August:
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025.
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
Financial updatesPharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a business update on Thursday, July 31, 2025.
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Corporate updatesFor media and investors only
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.